Developing new osteoarthritis treatments has proven to be a challenge, with no major breakthroughs in the past 40 years. Deeper knowledge about the pathophysiology of osteoarthritis is paving the way for the development of new innovative products – including cell and gene therapies -- to treat, and potentially even cure, OA.
Join our panel of PharmaLex and external experts as they describe the scientific journey into OA pathophysiology, possible paths for developing products in the field and how integrated product development can be applied to the development process to optimize and de-risk R&D.
Key learnings:
- Hear the latest insights into OA pathophysiology, current treatment and new therapeutic targets
- Understand the regulatory path for the development of different products, including new chemical entities, cell and gene therapies, and fixed-dose combination products
- Discover how IPD can help to shorten timelines, drive success in early clinical development and de-risk clinical research organisation
